Emad Shash: The role of adjuvant radiotherapy in postmenopausal women with early-stage ER+ breast cancer
Emad Shash, General Manager of the Breast Cancer Comprehensive Center of the National Cancer Institute at Cairo University, shared an article by Amira Mohamed Taha, et al. on LinkedIn:
“Exciting News!
Thrilled to share our latest systematic review and meta-analysis, published in Medicine, on the role of adjuvant radiotherapy (PORT) in postmenopausal women with early-stage ER-positive breast cancer!
Key Findings:
PORT significantly reduces local and regional recurrence in postmenopausal women with early-stage ER-positive, node-negative breast cancer.
However, PORT did not show a significant impact on distant relapse or overall survival.
What does this mean? We must carefully balance the benefits and risks of PORT to avoid overtreatment in low-risk patients.
This study provides valuable insights for clinical decision-making, supporting a personalized approach to breast cancer treatment.
Join the conversation!
Should adjuvant radiotherapy be standard for all, or should we refine selection criteria for treatment?
How do you approach de-escalation strategies in low-risk patients?
Grateful to my incredible co-authors Amira Mohamed Taha, Loay Kassem for this impactful work!
Let’s continue pushing the boundaries of evidence-based cancer care.”
Adjuvant radiotherapy in postmenopausal women with early-stage ER-positive breast cancer: A systematic review and meta-analysis.
Authors: Amira Mohamed Taha, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023